{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:40:58Z","timestamp":1777380058632,"version":"3.51.4"},"reference-count":73,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>Human immunodeficiency virus type-1 (HIV-1) antigenic variation poses a great challenge for vaccine immunogen design to elicit broadly neutralizing antibodies (bNAbs). Over the last 10\u201315 years, great progress has been made to understand the conserved sites of sensitivity on HIV envelope glycoprotein spikes targeted by bNAbs. Plasma neutralization mapping and monoclonal antibody isolation efforts have revealed five major conserved epitope clusters. Most of this work has focused on subtype B and C-infected Caucasian or African donors. It is not clear if the same epitopes and epitope rank order preferences are also true in donors infected with different HIV-1 subtypes and with different racial backgrounds. To investigate this point, in this study we report the first attempt to profile the bNAb specificities of CRF01_AE-infected Malaysian plasmas. We first measured neutralization titers of 21 plasmas against a subtype A, B, and AE pseudovirus panel. This revealed that 14% (3 of 21) plasmas had cross-clade breadth. Focusing on the cross-neutralizing plasma P9, we used AE and JR-FL mutant pseudoviruses, gp120 monomer interference, and native polyacrylamide gel electrophoresis to better understand the neutralization specificity. P9 demonstrates CD4-binding-site specificity with trimer dependence and D368 independence.<\/jats:p>","DOI":"10.1089\/aid.2020.0299","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T02:01:25Z","timestamp":1621389685000},"page":"162-172","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein"],"prefix":"10.1177","volume":"38","author":[{"given":"Qi Ron","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Sunway University, Bandar Sunway, Malaysia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok Keng","family":"Tee","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Binley","sequence":"additional","affiliation":[{"name":"HIV and Coronavirus Vaccine Development, San Diego Biomedical Research Institute, San Diego, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-8981","authenticated-orcid":false,"given":"Tommy","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Sunway University, Bandar Sunway, Malaysia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113425"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0103"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0235-7"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.14.7306-7321.2002"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.2.1100-1108.1996"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178746"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.02.013"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30647-9"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161853"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2016.512"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2015.504"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1996.12.629"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1071\/SH11121"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/08892220050195793"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0221"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01762-08"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00758-09"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02658-10"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.085"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05363-11"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001028"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13036"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01705-14"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.06.026"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.10.5678-5684.2003"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10108-10125.2005"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.2.835-844.2006"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis367"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.22.10134"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.359"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.7.3978-3988.1993"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11544"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.11.011"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.016"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1990.6.765"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.1016"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06938-11"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-2005-143-407"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.2.627-643.2000"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.03.015"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.4.2799-2809.1997"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004932"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00878-18"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005369"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02036-08"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.02.024"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008026"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01691-07"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/823605"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.13232-13252.2004"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415789111"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2008.12.008"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-016-0297-2"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.9.4199-4211.2002"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005988"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.03.017"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.1.642-658.2003"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-14"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02619-09"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233989"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006148"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.027"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.02.008"},{"key":"e_1_3_5_68_2","first-page":"930","article-title":"Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease","volume":"5","author":"D'Amelio R","year":"1992","unstructured":"D'Amelio R, , Biselli R, , Nisini R, et al.: Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. J Acquir Immune Defic Syndr (1988), 1992; 5:930\u2013935.","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0175-1"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01145-13"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01583-08"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00198-11"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000106"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-09"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2020.0299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:18Z","timestamp":1777367778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2020.0299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1089\/aid.2020.0299"],"URL":"https:\/\/doi.org\/10.1089\/aid.2020.0299","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}